Tirzepatide, a drug to treat obesity
A weekly dose for a year and a half has been shown to reduce weight by 21% in obese people
A weekly dose for a year and a half has been shown to reduce weight by 21% in obese people
First study in people with type 1 diabetes that demonstrates the relationship between poor control of glucose levels and an increased risk of foot ul1
The activity is part of a new project of the institution to publicize the research done by IDIBAPS to patients and patient associations.
Regenerating and protecting pancreatic beta cells, which are responsible for producing and secreting insulin, are two of the areas of research being1
Current tools to predict the risk of infarction or stroke have limited sensitivity, which is why research has focused on the identification of biomar1
IDIBAPS looks for talented professionals to meet the needs that appear periodically.
Enter